BACKGROUND: Hypertension (HTN) is an established class effect of vascular endothelial growth factor receptor (VEGFR) inhibition. In the phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT) trial, HTN was the most frequent adverse event of lenvatinib, an inhibitor of VEGFR1, VEGFR2, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), FGFR2, FGFR3, FGFR4, platelet-derived growth factor receptor a (PDGFRa), ret proto-oncogene (RET), and stem cell factor receptor (KIT). This exploratory analysis examined treatment-emergent hypertension (TE-HTN) and its relation with lenvatinib efficacy and safety in SELECT. METHODS: In the multicenter, double-blind SELECT trial, 392 patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC) were randomized 2:1 to lenvatinib (24 mg/d on a 28-day cycle) or placebo. Survival endpoints were assessed with Kaplan-Meier estimates and log-rank tests. The influence of TE-HTN on progression-free survival (PFS) and overall survival (OS) was analyzed with univariate and multivariate Cox proportional hazards models. RESULTS: Overall, 73% of lenvatinib-treated patients and 15% of placebo-treated patients experienced TE-HTN. The median PFS for lenvatinib-treated patients with (n 5 190) and without TE-HTN (n 5 71) was 18.8 and 12.9 months, respectively (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.39-0.88; P 5 .0085). For lenvatinib-treated patients, the objective response rate was 69% with TE-HTN and 56% without TE-HTN (odds ratio, 1.72; 95% CI, 0.98-3.01). The median change in tumor size for patients with and without TE-HTN was 245% and 240%, respectively (P 5 .2). The median OS was not reached for patients with TE-HTN; for those without TE-HTN, it was 21.7 months (HR, 0.43; 95% CI, 0.27-0.69; P 5 .0003). CONCLUSIONS: Although HTN is a clinically significant adverse event that warrants monitoring and management, TE-HTN was significantly correlated with improved outcomes in patients with RR-DTC, indicating that HTN may be predictive for lenvatinib efficacy in this population. Cancer 2018;124:2365-72.
INTRODUCTION
Hypertension (HTN) is an established on-target class effect of vascular endothelial growth factor receptor (VEGFR) inhibitors. 1 HTN is not only a common side effect of VEGFR inhibition but also has been shown to correlate with tumor response and survival in a variety of cancer settings, including non-small cell lung carcinoma, renal cell carcinoma, colorectal carcinoma, and pancreatic carcinoma. [2] [3] [4] [5] Lenvatinib is an oral, multikinase inhibitor of VEGFR1, VEGFR2, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), FGFR2, FGFR3, FGFR4, ret proto-oncogene (RET), stem cell factor receptor (KIT), and platelet-derived growth factor receptor a (PDGFRa). 6, 7 Lenvatinib has been approved in the United States, Europe, and Japan for the treatment of patients with locally recurrent or metastatic, progressive, radioiodine-refractory differentiated thyroid cancer (RR-DTC) on the basis of results from the pivotal phase 3 trial Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT).
The SELECT trial (NCT01321554) was a global, randomized, double-blind, multicenter study that demonstrated significant improvement in progression-free survival (PFS) and a high objective response rate (ORR) among patients with RR-DTC receiving treatment with lenvatinib compared with those receiving placebo. 9 The median PFS was 18.3 months for patients receiving lenvatinib and 3.6 months for patients receiving placebo (hazard ratio [HR] , 0.21; 99% confidence interval [CI] , 0.14-0.31; P < .001). 9 In addition, the ORR was 64.8% for patients receiving lenvatinib and 1.5% for patients receiving placebo (P < .001). 9 In the SELECT trial, the incidence of treatmentemergent adverse events of all grades was higher in the lenvatinib group (97.3%) compared with placebo group (59.5%). Among these, HTN was the most common treatment-emergent adverse event associated with lenvatinib treatment. 9 This exploratory analysis compared the efficacy and safety of lenvatinib in patients who experienced treatment-emergent hypertension (TE-HTN) with those of patients without TE-HTN in the SELECT trial.
MATERIALS AND METHODS

Study Design
The SELECT trial was a phase 3, randomized, multicenter, placebo-controlled study. All patients provided written informed consent, and the protocol was approved by all relevant institutional review bodies. This study was conducted in accordance with the Declaration of Helsinki and local laws. The full methodology for this study has been published previously. 9 Briefly, study patients were at least 18 years old and had the following: measurable, pathologically confirmed differentiated thyroid cancer; evidence of radioiodinerefractory disease (according to at least 1 of the following criteria: at least 1 measurable lesion without iodine uptake on any radioiodine scan, at least 1 measurable lesion that had progressed according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 within 13 months after radioiodine therapy despite radioiodine avidity at the time of treatment, or cumulative activity of radioiodine that was >600 mCi); and independently reviewed radiology (IRR) evidence of progression within the previous 13 months.
Eligible patients were stratified according to their geographic regions (Europe, North America, or other), ages (65 vs >65 years), and any prior VEGF-/VEGFRtargeted therapy (0 or 1). Patients could have preexisting HTN as long as their blood pressure (BP) was adequately controlled (150/90 mm Hg) with or without antihypertensive medications. In addition, patients on antihypertensive medications must have had no change in antihypertensive medications within 1 week prior to the start of study treatment. Patients were randomized 2:1 to receive oral lenvatinib (24 mg once daily) or placebo in 28-day cycles and received treatment until IRR-verified disease progression according to RECIST version 1.1 was reached. If IRR confirmed any disease progression, patients who were receiving placebo could elect to enter the open-label lenvatinib phase of the study.
Management of Hypertension
A prespecified management plan for TE-HTN was in place. BP was routinely measured at screening, at baseline, on days 1 and 15 of cycles 1 and 2, and on day 1 of every treatment cycle thereafter. Three BP measurements were taken at each visit, and the mean of these measurements was used to ensure accuracy. Once the study treatment began, patients with a confirmed systolic blood pressure (SBP) 140 mm Hg or a diastolic blood pressure (DBP) 90 mm Hg were administered an antihypertensive medication of the treating physician's choice. Patients with an SBP 160 mm Hg or a DBP 100 mm Hg had their BP measurements taken every 2 weeks until their SBP was 150 mm Hg and their DBP was 95 mm Hg for 3 consecutive months. Patients with a persistent SBP 160 mm Hg or DBP 100 mm Hg despite optimal clinical management had the study treatment dosages reduced. Dose interruptions and reductions were conducted sequentially (20, 14 , and 10 mg/d); further dose reductions required sponsor approval.
Statistical Analysis
This exploratory analysis included patients randomized to lenvatinib or placebo. Patients who were randomized to placebo and later received lenvatinib in the open-label extension of the study were considered part of placebo group only for this analysis. TE-HTN was defined as investigator-assessed HTN and included increased BP Survival endpoints were assessed with Kaplan-Meier estimates and were analyzed with log-rank tests. The influence of TE-HTN and other factors on PFS and overall survival (OS) were analyzed with a Cox proportional hazards model in a univariate analysis. Factors with P < .2 in the univariate analysis were included in a multivariate model.
Pharmacokinetic Analysis
A pharmacokinetic model was developed with pooled data from studies of healthy patients, patients with solid tumors, and patients with thyroid cancer (including the SELECT study). Details of the pharmacokinetic model have been reported previously. 10 The pharmacokinetic analysis also examined the relation between lenvatinib exposure and OS in the SELECT trial as well as the relation between lenvatinib exposure and the occurrence of HTN with pooled data from 3 studies of patients with RR-DTC.
RESULTS
Patients
The SELECT trial randomized 392 patients to receive lenvatinib (n 5 261) or placebo (n 5 131). At baseline, 56% of patients randomized to lenvatinib and 57% of patients randomized to placebo had HTN. More patients randomized to lenvatinib experienced TE-HTN (73%) compared with those randomized to placebo (15%; Table 1 ). For lenvatinib-treated patients, 47% experienced their first occurrence of TE-HTN during cycle 1 of treatment compared with 6% of placebo-treated patients. The first occurrence of worst-grade TE-HTN was also primarily in cycle 1 for both treatment groups (lenvatinib, 36%; placebo, 5%). Of the patients who had baseline renal impairment, 21 lenvatinib-treated patients (8%) and 3 placebo-treated patients (2%) had TE-HTN. Three lenvatinib-treated patients (1%) and 0 placebotreated patients discontinued treatment because of HTN.
TE-HTN and Efficacy
There was no difference in PFS improvement with lenvatinib between patients with and without baseline HTN (HR, 1.10; 95% CI, 0.75-1.61; P 5 .6290). However, lenvatinib-treated patients with TE-HTN showed a PFS advantage compared with those without TE-HTN (HR, 0.59; 95% CI, 0.39-0.88; unstratified log-rank P 5 .0085; Fig. 1 ). The median PFS for lenvatinib-treated patients with (n 5 190) and without TE-HTN (n 5 71) was 18.8 months (95% CI, 16.5 months to not estimable [NE] ) and 12.9 months (95% CI, 7.4 months to NE), respectively (HR, 0.59; 95% CI, 0.39-0.88; P 5 .0085). Further stratification of patients by TE-HTN grade did not show a significant difference in PFS between patients with grade 1 or 2 TE-HTN and patients with grade 3 or 4 TE-HTN (HR, 1.08; 95% CI, 0.64-1.83; log-rank P 5 .7691; Supporting Fig. 1) . However, the interpretation of this analysis was complicated by the high percentage of patients with baseline HTN. Lenvatinib-treated patients with TE-HTN also showed a significant OS advantage compared with those without TE-HTN (HR, 0.43; 95% CI, 0.27-0.69; logrank P 5 .0003; Fig. 2 ). Although the median OS for lenvatinib-treated patients with TE-HTN was not yet reached at the time of the data analysis, the median OS was 21.7 months (95% CI, 15.7 months to NE) for patients without TE-HTN. The 18-month OS rate was 78% (95% CI, 70.4%-83.7%) for lenvatinib-treated patients with TE-HTN and 58% (95% CI, 43.7%-69.0%) for patients without TE-HTN.
In addition, the ORR was 69% for lenvatinibtreated patients with TE-HTN and 56% for those without TE-HTN (odds ratio, 1.72; 95% CI, 0.98-3.01). However, the observed tumor shrinkage was similar in patients with and without TE-HTN. The median change in the tumor size for patients with and without TE-HTN was 245% and 240%, respectively (P 5 .2).
Safety and Management of TE-HTN
Concomitant antihypertensive medication was administered to 68% of lenvatinib-treated patients and 9% of placebo-treated patients (Table 2) . Among the lenvatinibtreated patients, 13% had a dose reduction, 13% had a dose interruption, and 1% discontinued the study treatment because of TE-HTN (Table 2 ). An analysis of adverse events indicated a potential association between TE-HTN and an increased likelihood of developing congestive heart failure as defined by the Common Terminology Criteria for Adverse Events version 4 (Table 3 ): 28% (54 of 190) of the patients with TE-HTN were found to develop congestive heart failure, whereas 14% (10 of 71) of the patients without TE-HTN developed congestive heart failure. However, the development of congestive heart failure did not appear to be influenced by either the duration of lenvatinib treatment or the severity of TE-HTN (Supporting Tables 1  and 2 ). Also, no correlation was found between TE-HTN and proteinuria in either the lenvatinib treatment group (Pearson's correlation coefficient 5 0.20) or placebo treatment group (Pearson's correlation coefficient 5 20.08).
TE-HTN as a Predictor of Clinical Efficacy
A univariate analysis indicated a statistically significant association between PFS and TE-HTN (P < .01), which was not maintained in the multivariate model (Table 4) . Use of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II antagonist (P < .01) and calcium channel blockers (P 5 .01) were also significantly associated with PFS in the univariate analysis but not in the multivariate model. Notably, most patients were administered more than 1 class of antihypertensive medication, and this might have confounded the analysis. In separate univariate analyses, TE-HTN, an ACE inhibitor or angiotensin II antagonist, and diuretics were significantly associated with OS (P < .01, P < .01, and P 5 .02, respectively; Table 5 ). However, when they were included in a multivariate model for OS, only TE-HTN remained significantly associated with OS (P 5 .04).
Pharmacokinetic Analysis
When evaluated as an ordered categorical logistic regression model, the best model describing the probability of HTN showed an effect of lenvatinib exposure (the logtransformed model predicted the minimum concentration during the dosing interval), with a higher occurrence and severity of TE-HTN associated with increased exposure. This exposure effect was estimated to be 1.58 times higher for Japanese patients. Despite this, lenvatinibtreated Japanese and non-Japanese patients with TE-HTN had similar efficacy outcomes (Supporting Figs. 2 and 3 and Supporting Table 3 ). Prior HTN was also found to increase the probability of experiencing TE-HTN in both Japanese and non-Japanese patients. However, the probability of experiencing TE-HTN was independent of age, weight, sex, or Eastern Cooperative Oncology Group performance status.
DISCUSSION
This exploratory analysis of the phase 3 SELECT trial demonstrated that lenvatinib-emergent HTN was significantly Abbreviations: CI, confidence interval; NE, not evaluable; TEAE, treatment-emergent adverse event (defined as an adverse event that occurred after the initiation of the study drug, regardless of severity); TE-HTN, treatment-emergent hypertension. Abbreviations: ACE, angiotensin-converting enzyme; CI, confidence interval; HR, hazard ratio; HTN, hypertension; TE-HTN, treatment-emergent hypertension.
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Cancer June 1, 2018 correlated with improved clinical outcomes for patients with RR-DTC. TE-HTN was the most common adverse event associated with lenvatinib treatment (73% of the patients treated with lenvatinib experienced TE-HTN compared with 15% of the patients receiving placebo). TE-HTN occurred early in the course of lenvatinib treatment, and 47% of the patients treated with lenvatinib experienced their first occurrence of TE-HTN during cycle 1 of treatment compared with 6% of the patients receiving placebo. TE-HTN was significantly correlated with both PFS and OS in the univariate analysis. However, when it was included in multivariate models, significance was maintained only in the correlation with OS. The loss of significance in the multivariate model for PFS may be due to statistical collinearity, in which a variable (in this case, TE-HTN) has a linear correlation with another variable. In this case, caution should be taken when interpreting results from the multivariate analysis. In addition, we note that the correlation between PFS and OS can vary with the tumor type, tumor stage, and drug being studied. 11, 12 Increased exposure to lenvatinib appeared to be correlated with a higher occurrence and severity of TE-HTN. The exposure effect was estimated to be higher in Japanese patients, possibly because of the increased lenvatinib exposure observed in the Japanese subpopulation of SELECT. 13 Correspondingly, 80% of Japanese patients on lenvatinib in SELECT experienced grade 3 or higher TE-HTN compared with 42% of the overall SELECT population. However, the efficacy outcomes of Japanese and non-Japanese lenvatinib-treated patients with TE-HTN did not differ significantly.
Exposure to lenvatinib is also a consideration because dose interruptions and/or reductions may be used to manage TE-HTN. A valid analysis of efficacy outcomes for patients with TE-HTN with and without dose modification is precluded in this study because of the small number of patients with TE-HTN who did not undergo dose modification (n 5 15). However, the impact of dose interruption on efficacy in SELECT has been investigated, with results showing that the median PFS was indeed longer in the group of patients with a shorter duration of dose interruption.
14 Importantly, the effect of lenvatinib dose intensity is currently under study in an appropriately designed and powered clinical trial contrasting differing lenvatinib starting doses (18 vs 24 mg) in patients with RR-DTC. 15 The management of TE-HTN is an important aspect of the overall clinical management strategy for patients receiving lenvatinib. Ensuring optimal management of TE-HTN with antihypertensive medications may allow the patient to obtain the maximal benefit from lenvatinib treatment, with dose reductions and interruptions reserved for patients whose HTN is not controlled with antihypertensive therapy alone. In the phase 3 SELECT trial, antihypertensive medication was administered to 68% of lenvatinib-treated patients and to 9% of placebo-treated patients. For the majority of lenvatinibtreated patients with TE-HTN, antihypertensive medication was sufficient to control the adverse event. Only 13% of lenvatinib-treated patients with TE-HTN had a dose reduction, 13% had a dose interruption, and 1% discontinued the study treatment because of TE-HTN. Still, a possible association between TE-HTN and an increased likelihood of developing congestive heart failure was found, highlighting the importance of monitoring and managing patients with TE-HTN. Although there are varied treatment options for HTN, our data do not allow us to speculate on the preferred antihypertensive therapy.
HTN is a demonstrated class effect of agents targeting the VEGF/VEGFR signaling pathway and has been encountered in studies of many agents, including sunitinib, bevacizumab, sorafenib, cediranib, and axitinib, in different tumor types. 1, 16, 17 For example, an association between TE-HTN and improved OS has been reported with bevacizumab when it has been added to chemotherapy for patients with non-small cell lung carcinoma. 2 Similar correlations have been shown with other VEGFR inhibitors in a variety of tumor types, including renal cell carcinoma, colorectal carcinoma, and pancreatic cancer. [3] [4] [5] As a result, HTN has been proposed as a biomarker of clinical outcomes for these agents. The higher incidence of severe HTN with lenvatinib treatment compared with other agents may be due to its more potent inhibition of VEGFR2. 18 One possible mechanism of VEGFR inhibitor-induced HTN may involve the interruption of endothelial cell survival signaling, which can lead to apoptosis and capillary rarefaction. 19 HTN induced by VEGFR inhibition could also occur because of the inhibition of endothelial production of nitric oxide, which can lead to constriction of vascular smooth muscle cells 20, 21 and activation of the endothelin-1 pathway. 22 In addition, there is some evidence that angiotensin receptor blockers and ACE inhibitors may provide some antitumor effects. 23 This analysis is limited by its exploratory nature. The study was not designed to examine the relation between TE-HTN and efficacy (ie, TE-HTN was a postrandomization and posttreatment event), so the results reported here do not definitively establish TE-HTN as a biomarker of lenvatinib efficacy because other baseline factors may still influence the outcome.
In conclusion, although HTN is a clinically significant adverse event that warrants careful monitoring and management, lenvatinib-emergent HTN was significantly correlated with improved clinical outcomes for patients with RR-DTC. With active management, HTN rarely requires discontinuation of lenvatinib. Further investigation is warranted to determine whether TE-HTN is indeed a predictive biomarker of lenvatinib efficacy in RR-DTC.
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